<p><strong>武田藥品工業株式會社</strong>（TSE:4502）的全年業績上週發佈，現在是回顧其表現的好時機。整體結果是積極的——儘管收入為 4.5 萬億日元與分析師的預測一致，但武田藥品交出了每股 122 日元的法定利潤，略高於預期。結果公佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將是很有意義的。因此，我們收集了最新的財報後法定共識估計，以查看明年可能會發生什麼。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461"/></p>
<p>TSE:4502 收益和收入增長 2026 年 5 月 15 日</p>
<p>在最新結果發佈後，覆蓋武田藥品的 14 位分析師現在預測 2027 年的收入為 4.61 萬億日元。如果實現，這將比過去 12 個月的收入增長 2.4%。每股收益預計將增長 13%，達到 137 日元。在這份報告發布之前，分析師們曾預測 2027 年的收入為 4.59 萬億日元，每股收益（EPS）為 161 日元。分析師們似乎在最新結果後變得更加悲觀。雖然收入預測沒有變化，但每股收益的預期確實有所下調。</p>
<p>查看我們對武田藥品的最新分析</p>
<p>可能會讓人驚訝的是，分析師們的共識目標價基本保持在 6,124 日元，顯然暗示預計收益的下降不會對估值產生太大影響。然而，過於關注單一目標價可能是不明智的，因為共識目標實際上是分析師目標價的平均值。因此，一些投資者喜歡查看估計範圍，以瞭解對公司估值是否存在分歧意見。對武田藥品的看法存在一些差異，最樂觀的分析師將其估值為 7,800 日元，而最悲觀的則為每股 4,900 日元。正如您所見，分析師們對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
<p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長預期進行比較來理解它們。我們要強調的是，武田藥品的收入增長預計將放緩，預計到 2027 年底的年化增長率為 2.4%，遠低於過去五年的歷史年均增長率 7.0%。相比之下，行業內其他有分析師覆蓋的公司預計年收入增長為 3.9%。考慮到增長放緩的預測，顯然武田藥品的增長也預計將低於其他行業參與者。</p>
<h2>結論</h2>
<p>最重要的是，分析師們下調了每股收益的預期，顯示出在這些結果發佈後情緒明顯下降。幸運的是，分析師們也重新確認了他們的收入預期，表明其與預期一致。儘管我們的數據確實表明武田藥品的收入預計將表現不及更廣泛的行業。共識目標價沒有實質性變化，表明最新估計並未對公司的內在價值產生重大影響。</p>
<p>考慮到這一點，我們不應急於對武田藥品下結論。長期的盈利能力遠比明年的利潤更為重要。在 Simply Wall St，我們有一系列到 2029 年的武田藥品分析師估計，您可以在我們的平台上免費查看。</p>
<p>話雖如此，仍然有必要考慮投資風險的潛在威脅。<strong>我們已識別出武田藥品的 3 個警示信號</strong>，理解這些信號應成為您投資過程的一部分。</p>
<h3>估值複雜，但我們在這裏為您簡化。</h3>
<p>通過我們的詳細分析，發現武田藥品是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
<p>訪問免費分析</p>

4502

<p>武田藥品工業株式會社報告每股法定利潤為 122 日元，超出分析師預期，而收入與預測一致，達到 4.5 萬億日元。分析師預測到 2027 年收入將適度增長至 4.61 萬億日元，但已下調每股收益預期至 137 日元，反映出情緒的下降。共識目標價保持不變，為 6,124 日元，儘管與行業同行相比增長放緩，但仍顯示出穩定的估值。分析師強調了三個投資者需要考慮的警示信號</p>

<p>The full-year results for <strong>Takeda Pharmaceutical Company Limited</strong> (TSE:4502) were released last week, making it a good time to revisit its performance. The result was positive overall - although revenues of JP¥4.5t were in line with what the analysts predicted, Takeda Pharmaceutical surprised by delivering a statutory profit of JP¥122 per share, modestly greater than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.</p>
<div class="lb-trans"><p><strong>武田藥品工業株式會社</strong>（TSE:4502）的全年業績上週發佈，現在是回顧其表現的好時機。整體結果是積極的——儘管收入為 4.5 萬億日元與分析師的預測一致，但武田藥品交出了每股 122 日元的法定利潤，略高於預期。結果公佈後，分析師們更新了他們的盈利模型，瞭解他們是否認為公司的前景發生了重大變化，或者一切如常，將是很有意義的。因此，我們收集了最新的財報後法定共識估計，以查看明年可能會發生什麼。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461" alt="" original-src="https://images.simplywall.st/asset/chart/874540-earnings-and-revenue-growth-1-dark-2/1778880783461"/></p>
<p>TSE:4502 Earnings and Revenue Growth May 15th 2026</p>
<div class="lb-trans"><p>TSE:4502 收益和收入增長 2026 年 5 月 15 日</p>
</div><p>After the latest results, the 14 analysts covering Takeda Pharmaceutical are now predicting revenues of JP¥4.61t in 2027. If met, this would reflect an okay 2.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 13% to JP¥137. In the lead-up to this report, the analysts had been modelling revenues of JP¥4.59t and earnings per share (EPS) of JP¥161 in 2027. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates.</p>
<div class="lb-trans"><p>在最新結果發佈後，覆蓋武田藥品的 14 位分析師現在預測 2027 年的收入為 4.61 萬億日元。如果實現，這將比過去 12 個月的收入增長 2.4%。每股收益預計將增長 13%，達到 137 日元。在這份報告發布之前，分析師們曾預測 2027 年的收入為 4.59 萬億日元，每股收益（EPS）為 161 日元。分析師們似乎在最新結果後變得更加悲觀。雖然收入預測沒有變化，但每股收益的預期確實有所下調。</p>
</div><p>Check out our latest analysis for Takeda Pharmaceutical</p>
<div class="lb-trans"><p>查看我們對武田藥品的最新分析</p>
</div><p>It might be a surprise to learn that the consensus price target was broadly unchanged at JP¥6,124, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Takeda Pharmaceutical, with the most bullish analyst valuing it at JP¥7,800 and the most bearish at JP¥4,900 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>可能會讓人驚訝的是，分析師們的共識目標價基本保持在 6,124 日元，顯然暗示預計收益的下降不會對估值產生太大影響。然而，過於關注單一目標價可能是不明智的，因為共識目標實際上是分析師目標價的平均值。因此，一些投資者喜歡查看估計範圍，以瞭解對公司估值是否存在分歧意見。對武田藥品的看法存在一些差異，最樂觀的分析師將其估值為 7,800 日元，而最悲觀的則為每股 4,900 日元。正如您所見，分析師們對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
</div><p>Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Takeda Pharmaceutical's revenue growth is expected to slow, with the forecast 2.4% annualised growth rate until the end of 2027 being well below the historical 7.0% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 3.9% per year. Factoring in the forecast slowdown in growth, it seems obvious that Takeda Pharmaceutical is also expected to grow slower than other industry participants.</p>
<div class="lb-trans"><p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長預期進行比較來理解它們。我們要強調的是，武田藥品的收入增長預計將放緩，預計到 2027 年底的年化增長率為 2.4%，遠低於過去五年的歷史年均增長率 7.0%。相比之下，行業內其他有分析師覆蓋的公司預計年收入增長為 3.9%。考慮到增長放緩的預測，顯然武田藥品的增長也預計將低於其他行業參與者。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Takeda Pharmaceutical's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最重要的是，分析師們下調了每股收益的預期，顯示出在這些結果發佈後情緒明顯下降。幸運的是，分析師們也重新確認了他們的收入預期，表明其與預期一致。儘管我們的數據確實表明武田藥品的收入預計將表現不及更廣泛的行業。共識目標價沒有實質性變化，表明最新估計並未對公司的內在價值產生重大影響。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Takeda Pharmaceutical. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Takeda Pharmaceutical going out to 2029, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考慮到這一點，我們不應急於對武田藥品下結論。長期的盈利能力遠比明年的利潤更為重要。在 Simply Wall St，我們有一系列到 2029 年的武田藥品分析師估計，您可以在我們的平台上免費查看。</p>
</div><p>That said, it's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 3 warning signs</strong> with Takeda Pharmaceutical , and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>話雖如此，仍然有必要考慮投資風險的潛在威脅。<strong>我們已識別出武田藥品的 3 個警示信號</strong>，理解這些信號應成為您投資過程的一部分。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值複雜，但我們在這裏為您簡化。</h3>
</div><p>Discover if Takeda Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現武田藥品是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>訪問免費分析</p>
</div>

武田藥品工業株式會社剛剛錄得每股收益超預期 8.6%：以下是分析師的後續預測